Aligos Therapeutics, Inc. (ALGS)
About Aligos Therapeutics, Inc.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $2.2M
- Net income
- -$24.2M
- Total assets
- $88.5M
- Market cap
- $30.4M
- Operating margin
- -4024.9%
- Net margin
- -1106.7%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $2.2M
- Operating expenses
- $90.2M
- Operating income
- -$88.0M
- Income tax
- $314.0K
- Net income
- -$24.2M
- EPS (basic)
- $-2.45
- EPS (diluted)
- $-2.45
Balance sheet
- Total assets
- $88.5M
- Current assets
- $82.9M
- Total liabilities
- $35.0M
- Current liabilities
- $21.2M
- Shareholders’ equity
- $53.5M
Cash flow
- Operating cash flow
- -$82.5M
- Investing cash flow
- -$37.8M
- Financing cash flow
- $101.6M
- Net cash flow
- -$18.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $30.4M
- EPS (diluted)
- $-2.45
- Shares outstanding
- 7.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 16, 2020
Aligos Therapeutics, Inc. (ALGS) Stock Price
- Reported a net loss of $24.2M in FY2025.
- Revenue declined 50% from FY2021 to FY2025.
- Trading 69% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Aligos Therapeutics, Inc..
Write a review
News about Aligos Therapeutics, Inc.
News & sentiment via Polygon.io
Aligos Therapeutics, Inc.: frequently asked questions
Is Aligos Therapeutics, Inc. an American company?
Aligos Therapeutics, Inc. is a US-based company headquartered in South San Francisco, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Aligos Therapeutics, Inc. headquartered?
Aligos Therapeutics, Inc. is headquartered in South San Francisco, California, United States.
Is Aligos Therapeutics, Inc. publicly traded?
Yes — Aligos Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol ALGS on the NASDAQ.
What does Aligos Therapeutics, Inc. do?
Aligos Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
